Biotechnology News and Research

RSS

Antibodies produced by shark immune systems could be used to detect human pathogens

A recent discovery shows that antibodies produced by shark immune systems could be used to detect a range of human pathogens some of which have the potential to be used as biological warfare agents.

20 Aug 2004

Major expansion of research and development facilities at The Centre for Life

The Centre for Life has unveiled plans which will help develop Newcastle’s position as a world leader in the fields of innovation and research.

18 Aug 2004

Scientists have successfully filmed individual cells migrating within a functioning lymph node

The researchers hope to gain a deeper understanding of how our immune system functions from their detailed study of lymph node processes.

17 Aug 2004

Device to warn astronauts about the presence of harmful compounds inside spacecraft

U.S. Rep. John Duncan presented a check for $1.48 million to the University of Tennessee Center for Environmental Biotechnology Wednesday.

13 Aug 2004

Ways to economically recover recombinant proteins from transgenic tobacco

The economics of producing biopharmaceuticals from transgenic plants such as tobacco is still a roadblock to producing large quantities of urgently needed medicines, especially for people in underdeveloped nations.

12 Aug 2004

New biotech alliance to focus on diseases of nerve injury and pain

NeuroTargets Ltd, a discovery-led biotechnology company ‘spun-out’ from the University of Bristol, has formed an exciting new alliance with BioFocus plc, a world leader in collaborative drug discovery, to focus on diseases of nerve injury and pain.

11 Aug 2004

Clinical trial of lipase inhibitor for the treatment of obesity

Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability and pharmacokinetics of GT389-255, a lipase inhibitor conjugated to a fat binding polymer for the treatment of obesity.

9 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

Cyntellect issued patent covering LaserFect(TM) technology

Cyntellect a privately-held biotechnology company, has announced the issuance of U.S. Patent No. 6,753,161 covering the Company's LaserFect(TM) technology.

6 Aug 2004

Zyomyx issued five new biotech patents

Zyomyx a privately held biotechnology company, has announced that the United States Patent and Trademark Office issued five new patents to the Company. With these additions, Zyomyx has further strengthened its proprietary position in the area of protein biochip technology development and commercialization.

6 Aug 2004

Automated science speeds solution of Human Genome data

Scientists in Argonne's Biosciences Division are automating and accelerating the complex processes that coax a protein to reveal its structure so they can learn the role Nature assigned it.

6 Aug 2004

Australian university signs multi-million dollar anti-cancer research deal

Australia's University of Newcastle Research Associates (TUNRA) Ltd has signed a licensing agreement worth approximately $10 million with the biotechnology company Psiron Ltd to develop anti-cancer treatments.

5 Aug 2004

Promising new cancer drug, Nanotax

A Lawrence company that uses patented technology created at the University of Kansas to improve the effectiveness of drugs has won a $100,000 National Institutes of Health grant to support further testing of the company's promising new cancer drug, Nanotax.

5 Aug 2004

Renal research boost for the University of Birmingham

The Medical School at the University of Birmingham is amongst four UK winners of the prestigious Genzyme Renal Innovations Programme (GRIP).

2 Aug 2004

New approach to cancer vaccines may eradicate skin cancer tumors

Mayo Clinic and British researchers have developed a new approach to cancer vaccines that purposely kills healthy skin cells to target the immune system against tumors. The new approach has eradicated skin cancer tumors in mice.

2 Aug 2004

Philadelphia diet drug trial completed

Wyeth has announced that the jury in the case of Rhonda Istnick and Henry Clepper v. Wyeth, et al. rendered its decision, finding in favor of the Company in the case brought by Ms. Istnick, while awarding Mr. Clepper compensatory damages in the amount of $48,000.

29 Jul 2004

New method for detecting premature birth

Researchers at Oregon Health & Science University have discovered a method for detecting intra-amniotic infections in pregnant women using state-of-the-art methods.

29 Jul 2004

$1.6 million to develop gene therapy strategies for Duchenne muscular dystrophy, a fatal, childhood-onset disease

The Muscular Dystrophy Association has announced it has awarded $1.6 million to Asklepios, a biotechnology company closely allied with the University of North Carolina at Chapel Hill, to develop gene therapy strategies for Duchenne muscular dystrophy (DMD), a fatal, childhood-onset disease.

23 Jul 2004

Environmental Proteomics to design antibodies for the global market

The business fills a niche in the world market by manufacturing custom-made tools (antibodies) used in the study of proteins. Antibodies for use in typical laboratory subjects such as mammals are easily obtained, but it is very difficult to find these tools for use with other organisms, such as fish, plants, and algae. Recognizing the need for these products through his own research at Mount A over the last six years, Campbell appreciated the innovative applications of his findings.

21 Jul 2004

3M and MicroDose Technologies Inc. team up to bring advanced electronic dry powder inhaler to market

3M and MicroDose Technologies Inc., a privately held drug delivery company based in Monmouth Junction, N.J., announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.

20 Jul 2004